Total Voting Rights

Summary by AI ^BETAClose X

RTW Biotech Opportunities Ltd has announced its total voting rights as of April 30, 2026. The company currently has 345,967,440 ordinary shares in issue, with 22,320,003 held in treasury, resulting in a total of 323,647,437 voting rights. This figure serves as the denominator for shareholders to calculate any notification requirements under the FCA's Disclosure Guidance and Transparency Rules.

Disclaimer*

RTW Biotech Opportunities Ltd

01 May 2026

LEI: 549300Q7EXQQH6KF7Z84

1 May 2026

RTW Biotech Opportunities Ltd
(the "Company")

Total Voting Rights

In accordance with DTR 5.6.1 of the FCA's Disclosure Guidance and Transparency Rules, the Company notifies the following:

As at the close of business on 30 April 2026, the Company had 345,967,440 Ordinary Shares in issue, of which 22,320,003 were held in treasury. Therefore, the total number of voting rights in the Company at that date was 323,647,437.

The above figure of 323,647,437 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

Enquiries:

RTW Investments, LP - Investment Manager

Oliver Kenyon (Business & Corporate Development)

Krisha McCune (Investor Relations)

+44 (0)20 7959 6362

biotechopportunities@rtwfunds.com

Altum (Guernsey) Limited

Joanna Duquemin Nicolle

Sadie Morrison

+44 (0)1481 703 100

About RTW Biotech Opportunities Ltd:

RTW Biotech Opportunities Ltd (LSE: RTW) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Biotech Opportunities Ltd invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives. RTW Biotech Opportunities Ltd is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.

Visit the website at www.rtwbio.com for more information.

***********

The information in this announcement may include forward-looking statements, which are based on the current expectations and projections about future events, and in certain cases can be identified by the use of terms such as "may", "will", "should", "expect", "anticipate", "project", "estimate", "intend", "continue", "target", "believe" (or the negatives thereon) or other variations thereon or comparable terminology. These forward-looking statements are subject to risks, uncertainties and assumptions, and therefore the events in the forward-looking statements may not occur.

***********

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END